佐匹克隆与艾司唑仑治疗老年失眠症的临床疗效比较

右佐匹克隆治疗老年原发性失眠症的效果分析发表时间：2018-11-21T09:58:42.540Z 来源：《世界复合医学》2018年第09期作者：于庆华[导读] 将右佐匹克隆用于老年原发性失眠患者的临床治疗中具有更好的疗效和更高的治愈率。

齐齐哈尔民康医院黑龙江齐齐哈尔 161000摘要：目的：探讨应用右佐匹克隆治疗老年原发性失眠症的临床疗效。

方法：选取近一以年来在我院接受治疗的76例老年原发性失眠症患者，随机分为观察组和对照组，每组各38人，观察组使用右佐匹克隆片(1～3mg)，对照组使用艾司唑仑片(1～2mg)。

疗程均为30d。

采用匹兹堡睡眠质量指数(PSQI)记录和观察两组患者的睡眠变化情况及不良反应，评估两组患者的睡眠质量。

结果：观察组患者的睡眠质量改善程度优于对照组，差异存在统计学意义(P<0.05)。

结论：将右佐匹克隆用于老年原发性失眠患者的临床治疗中具有更好的疗效和更高的治愈率。

关键词：右佐匹克隆；老年原发性失眠；临床效果Effect of zopiclone in the treatment of elderly patients with primary insomniaAbstract:Objective:To investigate the clinical efficacy of zopiclone in the treatment of elderly patients with primary insomnia. Methods:Sixty-six elderly patients with primary insomnia who were treated in our hospital in the past year were randomly divided into observation group and control group,with 38 persons in each group.The observation group used dextrozole tablets(1~3mg) once a night;the control group used estazolam tablets(1~2mg),once a night.The Pittsburgh Sleep Quality Index(PSQI) was used to record and observe sleep changes and adverse reactions in the two groups,and the sleep quality of the two groups was evaluated.Results:The improvement of sleep quality in the observation group was better than that in the control group,and the difference was statistically significant(P<0.05).Conclusion:The use of zopiclone in the clinical treatment of elderly patients with primary insomnia has better curative effect and higher cure rate.Key words:zopiclone;primary insomnia in elderly;clinical effect失眠症是老年人当中最常见的睡眠障碍，原发性失眠症在老年群体当中的发病率是普通人群的10倍以上，造成疲倦、情绪低落,记忆力减退等问题，加重甚至诱发一些如精神方面疾病，如抑郁障碍，以及消化性溃疡、心血管疾病等。

-264-国际精神病学杂志JOURNAL OF INTERNATIONAL PSYCHIATRY 2021年第48卷第2期右佐匹克隆与艾司唑仑治疗老年痴呆伴睡眠障碍患者的比较何明1郑芝伟2【摘要】目的比较右佐匹克隆与艾司唑仑治疗老年痴呆伴睡眠障碍患者的效果和不良反应。

方法本研究纳入对象为2018年2月〜2020年2月就诊的86例老年痴呆症伴睡眠障碍患者，随机分 为对照组与观察组，对照组给予艾司唑仑治疗，观察组采用右佐匹克隆治疗。

所有患者在治疗前后 评估匹兹堡睡眠指数量表（PSQI )、生活能力量表（ADL )、简易精神状况检查表（MMSE )以及病理行为评分表（BEHA VE -AD )，比较不良反应发生情况。

结果两组治疗后PSQI 评分均降低，ADL 评分、MMSE 评分均升高，且治疗后观察组MMSE 评分、BEHAVE-AD 评分均优于对照组（/^O .OS )，两组PSQI 评分差异无统计学意义（尸>0.05);两组治疗后BEHAVE-AD 量表各维度评分均降低，且 治疗后观察组低于对照组（P <0.05);观察组不良反应发生率低于对照组（P >0.05)。

结论右佐匹克隆与艾司唑仑改善老年痴呆症伴睡眠障碍的疗效相当，但右佐匹克隆不良反应发生率更低，还有 助于提升患者的认知功能与活动能力。

【关键词】右佐匹克隆；艾司唑仑；老年痴呆症；睡眠障碍【中图分类号】R749.053【文献标识码】A【文章编号】1673-2952 (2021) 02-0264-03Comparison of the efficacy of dexzopiclone and estazolam in senile dementia patients with sleep disordersH E M in gy Z H E N G Z h iw e i . D e p a rtm e n t o f P h a r m a c y , F irst A ffilia te d H o sp ita l o f H en a n U n iv e rs ity , Z h en g zh ou475000，C h in a【Abstract 】Objective To compare the efficacy of dexzopiclone and estazolam in senile dementia patients w ithsleep disorders . Methods Eighty-six patients with dementia and sleep disorders from February 2018 to February 2020 were included and randomly divided into the control group and the observation group . The control group was treated w ith estazolam , and the observation group was treated with dexzopiclone . Before and after treatment , all the patients were evaluated by the Pittsburgh sleep index scale (PSQI ), vitality scale (ADL ), mini-mental state examination ( MMSE ), and Pathological behavior score ( BEHA VE—AD ) . The occurrence of adverse reactions were compared . Results After treatment , PSQI score in both of two groups decreased significantly , and the ADL score and M M SE score in ­creased significantly ( P <0.05 ), while the M M SE score and BEHA VE-AD score of the observation group were better than those of the control group ( P <0.05 ) . There was no significant difference in PSQ I score between the two groups (P >0.05 ) . The scores of each dimension of the BEHA VE-AD scale of the tw o groups were significantly reduced after treatment , and the observation group was significantly lower than the control group ( P <0.05 ) . The incidence of ad ­verse reactions in the observation group was significantly lower than that in the control group (P >0.05) . Conclusion Ezopiclone and estazolam have the same effect in improving sleep disorders in senile dementia patients with sleep dis ­orders ,but dexzopiclone not only has a low incidence of adverse reactions , but also helps to improve patients ' cognitive function and mobility .【Key words 】Dexzopiclone ; Estazolam ; Senile dementia ; Sleep disorders老年痴呆症主要影响患者记忆、语言、认知等 以及睡眠-觉醒周期紊乱与老年痴呆症神经功能缺多种功能，还可能出现睡眠质量下降[|]。

右佐匹克隆与艾司唑仑治疗慢性失眠症的疗效及安全性评价胡吉号【摘要】目的探讨右佐匹克隆与艾司唑仑治疗慢性失眠症的疗效及安全性.方法100例慢性失眠症患者, 按治疗方法差异性分为研究组和对照组, 各50例.研究组给予右佐匹克隆治疗, 对照组给予艾司唑仑治疗, 比较两组治疗不同时间段 (治疗前及治疗7、14、28 d) 阿森斯失眠量表评分及不良反应发生情况、治疗效果.结果治疗前两组阿森斯失眠量表评分比较差异无统计学意义 (P＞0.05) ;治疗7、14、28 d研究组阿森斯失眠量表评分均低于对照组, 差异有统计学意义 (P＜0.05) .研究组出现1例口苦患者, 不良反应发生率为2.00％;对照组出现3例疲乏、2例记忆力下降、2例食欲下降患者, 不良反应发生率为14.00％;研究组不良反应发生率低于对照组, 差异有统计学意义 (P＜0.05) .研究组总有效率96.00％高于对照组的84.00％, 差异有统计学意义 (P＜0.05) .结论与艾司唑仑相比, 右佐匹克隆治疗慢性失眠症疗效肯定, 能够明显改善患者失眠症状, 安全性也更高.%Objective To discuss the efficacy and safety of eszopiclone and estazolam in the treatment of chronic insomnia. Methods A total of 100 chronic insomnia patients were divided by different treatment methods into research group and control group, with 50 cases in each group. The research group was treated with eszopiclone, and the control group was treated with estazolam. Comparison were made on Ascens insomnia scale, occurrence of adverse reactions and treatment effect of the two groups at different time points (before treatment and 7, 14, 28 d after treatment). Results Before treatment, both groups had no statistically significant difference in Ascens insomnia scale score (P＞0.05). After 7, 14, 28 d of treatment, theresearch group had lower Ascens insomnia scale score than the control group, and the difference was statistically significant (P＜0.05). The research group had 1 case of bitter taste, with incidence of adverse reactions as 2.00％, while the control group had 3 cases of fatigue, 2 cases of memory loss and 2 cases of anorexia, with incidence of adverse reactions as 14.00％. The research group had lower incidence of adverse reactions than the control group, and the difference was statistically significant (P＜0.05). The research group had higher total effective rate as 96.00％ than 84.00％ in the control group, and the difference was statistically significant (P＜0.05). Conclusion Compared with estazolam, eszopiclone shows affirmative efficacy in treating chronic insomnia, and it can obviously improve insomnia symptom with higher safety.【期刊名称】《中国实用医药》【年(卷),期】2019(014)005【总页数】2页(P108-109)【关键词】右佐匹克隆;艾司唑仑;慢性失眠症;疗效;安全性【作者】胡吉号【作者单位】湖北六七二中西医结合骨科医院 430079【正文语种】中文随着生活节奏的加快, 工作压力的增加, 使得失眠症发病率逐年提高。

佐匹克隆与艾司唑仑治疗失眠症的疗效比较吴佩炯;王伟松;韩水华【期刊名称】《浙江医学》【年(卷),期】2014(000)004【总页数】2页(P336-337)【作者】吴佩炯;王伟松;韩水华【作者单位】311800 诸暨市第五人民医院心身科;311800 诸暨市第五人民医院心身科;311800 诸暨市第五人民医院心身科【正文语种】中文非苯二氮卓类催眠药物不影响人的正常睡眠生理结构，且次日早晨无残留效应，不易产生耐药性和药物成瘾性，无反跳性失眠[1]，已成为治疗失眠症的首选。

目前国内临床常使用的非苯二氮卓类催眠药物有唑吡坦、佐匹克隆、扎来普隆等。

临床试验显示佐匹克隆起效快，且药效可维持6h，低剂量诱导睡眠，高剂量保证睡眠质量[2]。

本研究采用佐匹克隆片治疗失眠症患者，并与临床应用较为普遍的苯二氮卓类药物艾司唑仑比较，评价国产佐匹克隆治疗失眠症的疗效和不良反应，现将结果报道如下。

1.1 对象收集2010-10—2012-12在本院精神心理门诊及病区住院，且符合“中国精神疾病分类与诊断标准第3版（CCMD-3）”、“失眠症”诊断标准[3]的患者共110例，男62例，女48例；年龄18～65岁，平均（45.6± 21.3）岁；汉密尔顿抑郁量表（HAMD）[4]＜17分。

患者均签署书面知情同意书。

排除标准：（1）研究前1周使用过抗精神病药、抗抑郁药者；（2）合并其它各系统严重疾病者；（3）酒、药物依赖者；（4）妊娠或哺乳妇女及重症精神病患者。

按随机数字表法分为两组，研究组55例，男32例，女23例，年龄28～64岁，平均（46.5±18.3）岁；病程12～54个月，平均（33.6±21.7）个月。

对照组55例，男30例，女25例，年龄25～69岁，平均（47.7±22.8）岁；病程11～57个月，平均（34.5±23.6）个月。

两组患者性别、年龄及病程的差异均无统计学意义（均P＞0.05）。